Demecan supports the inter-associational statement of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) on the new draft guideline of the Federal Joint Committee (G-BA) regarding the future handling of cannabis as medicine. The statements of various associations have been submitted to the G-BA.
The draft directive includes, among other things, the proposal to prescribe and reimburse dried cannabis flowers in the future only after special justification. The authorization to issue prescriptions for cannabis-based medicines is also to be limited to certain specialists, according to the draft directive.
For more information:
Demecan
info@demecan.de
www.demecan.de